ClinicalTrials.gg
CompletedNCT02743013Updated Jul 2, 2021

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

A Phase 1 interventional study of CHF 5993 100/6/12,5 pMDI and CHF 5993 100/6/12,5 DPI Test 1 in COPD, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-02.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Enrollment
35th of 59
50 · median 65
Started
2016
with 7 others
Phase 1
21 of 68
none open now
Registered
32nd of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is the 35th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2016, is one of 21 in phase 1, and was the 32nd registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

This clinical pharmacology study is performed to evaluate the total systemic exposure and the lung availability of CHF 5993 DPI and pMDI with and without valved holding chamber, in healthy volunteers.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject's written obtained prior to any study related procedure.
  2. Ability to understand the study procedures, the risks involved, and ability to be trained to use the pMDI device correctly with AIM™ (Aerosol Inhalation Monitor) Vitalograph®.
  3. Ability to generate sufficient PIF (at least 40 L/min) using the In-Check device simulating NEXThaler® device.
  4. Male and female Caucasian subjects aged 18 to 55 years inclusive.
  5. (BMI) within the range of 18 to 30 kg/m2 inclusive.
  6. Non-smokers or ex-smokers who smoked \< 5 pack years (pack-years = the number of cigarette packs per day, times the number of years) and stopped smoking > 1 year prior to screening.
  7. Good physical and mental status, determined on the basis of the medical history and a general clinical examination, at screening and before randomization.
  8. Lung function measurements within normal limits (Normal values: /FVC is > 0.70 and FEV1 > 80% predicted).
  9. Female subject of non- (WONCBP) defined as physiologically incapable of becoming pregnant (i.e. or permanently sterile) and female subjects of childbearing potential (WOCBP) fulfilling one of the following criteria:

    • WOCBP with fertile male partners: they and/or their partner of childbearing potential must be willing to use a double barrier method including one highly effective birth control method and one acceptable birth control method (male or female condom with or without spermicide and/or cap, diaphragm or sponge with spermicide), from the signature of the informed consent and until 3 months after follow-up visit;
    • WOCBP with non-fertile male partners: contraception is not required in this case.

Exclusion criteria

Exclusion Criteria:

  1. Blood donation (equal or more than 450 ml) or blood loss, less than 8 weeks prior screening or prior randomization.
  2. Abnormal level defined as \< 10.5 g/dl
  3. For females only: pregnant and lactating female subjects, confirmed by a positive serum test at screening and/or urine test before randomization.
  4. Positive HIV1 or HIV2 serology.
  5. Positive results from the Hepatitis serology which indicates acute or chronic or .
  6. Unsuitable veins for repeated venipuncture.
  7. Documented history of alcohol abuse within 12 months prior to screening.
  8. Documented history of drug abuse within 12 months prior to screening, or positive urine drug test performed at screening and/or before randomization.
  9. Subjects who have a positive urine test for cotinine at screening and/or before randomization.
  10. abnormal laboratory values, suggesting an unknown disease and requiring further clinical investigation.
  11. Clinically relevant and uncontrolled respiratory, cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol.
  12. Subjects with medical diagnosis of narrow-angle glaucoma, prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic.
  13. Subjects with history of asthma, including childhood asthma.
  14. Known intolerance/ to any of the contained in any of the formulations used in the trial.
  15. Abnormal 12-lead digitized (12-lead ECG) parameter (i.e.: QRS > 120 msec and/or PR > 220 msec and/or HR \< 40 bpm and/or HR > 110 bpm and/or > 450 ms for males or QTcF > 470 ms for female, considering the average from triplicate) or 12-lead ECG evaluated as abnormal clinical significant by the investigator, at screening.
  16. Abnormal Blood Pressure (i.e.: Diastolic Blood Pressure > 90 mmHg and/or Systolic Blood Pressure > 140 mmHg, considering the average from triplicate) at screening.
  17. Participation in another clinical trial where investigation drug was received less than 8 weeks prior to screening.
  18. Subject taking any drug treatment, including prescribed or OTC medicines as well as vitamins, homeopathic remedies etc, in the 14 days before the screening, with the exception of :

    1. Occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions);
    2. Hormonal ;
    3. Hormonal replacement treatment for women.
  19. Subject taking enzyme-inducing drugs, enzyme-inhibiting drugs, biologic drugs or any drug known to have a well-defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole) in the 3 months before screening.
  20. Heavy caffeine drinker (> 5 caffeinated beverages e.g., coffee, tea, cola per day).
  21. Subject who has had a lower respiratory tract infection within 4 weeks prior to screening or prior randomization.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    CHF 5993 100/6/12,5 pMDI

    with/without Charcoal Block

    Drug: CHF 5993 100/6/12,5 pMDI

  • Active comparator
    CHF 5993 100/6/12,5 pMDI (replicate)

    with/without Charcoal Block

    Drug: CHF 5993 100/6/12,5 pMDI replicate

  • Active comparator
    CHF 5993 100/6/12,5 pMDI VHC

    with/without Charcoal Block with Valved Holding Chamber

    Drug: CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber

  • Experimental
    CHF 5993 100/6/12,5 DPI test 1

    with/without Charcoal Block

    Drug: CHF 5993 100/6/12,5 DPI Test 1

  • Experimental
    CHF 5993 100/6/12,5 DPI test 2

    with/without Charcoal Block

    Drug: CHF 5993 100/6/12,5 DPI Test 2

Interventions

  • DrugCHF 5993 100/6/12,5 pMDI
  • DrugCHF 5993 100/6/12,5 DPI Test 1
  • DrugCHF 5993 100/6/12,5 DPI Test 2
  • DrugCHF 5993 100/6/12,5 pMDI replicate
  • DrugCHF 5993 100/6/12,5 pMDI with Valved Holding Chamber
06

What researchers measure

Primary outcomes

  1. Evaluation of the area under the curve (AUC0-t) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.

    AUC0-t

    Time frame: 72 hours after adminstration

  2. Evaluation of the Area under the curve (AUC) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.

    AUC 0-t

    Time frame: 72 hours after adminstration

  3. Evaluation of the Maximum Plasma Concentration (Cmax) for the systemic exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide.

    Cmax

    Time frame: 72 hours after adminstration

  4. Evaluation of the Maximum Plasma Concentration (Cmax) for the lung exposure of B17MP (active metabolite of Beclometasone Dipropionate), Formoterol and Glycopirronium Bromide after charcoal blockage.

    Cmax

    Time frame: 72 hours after adminstration

Secondary outcomes

  1. Evaluate the Area Under the Curve of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage

    Area Under the Curve

    Time frame: 72 hours after adminstration

  2. Evaluate the Maximum Plasma Concentration of Beclometasone Dipropionate, B17MP (active metabolite of Beclometasone Dipropionate), formoterol and Glycopirronium bromide with and without charcoal blockage

    Maximum Plasma concentration

    Time frame: 72 hours after adminstration

  3. Evaluate the number of Adverse events and adverse drug reactions

    Time frame: 72 hours after adminstration

  4. Evaluation of Blood pressure

    Measurement of Blood pressure

    Time frame: 72 hours after adminstration

  5. Evaluation of the heart rate

    Measurement of Heart rate

    Time frame: 72 hours after adminstration

07

Study locations

1 site
  • SGS CPU Antwerpen
    Antwerpen, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2016, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
Apr 19, 2016
Start
Apr 2016
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Last update
Jul 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02743013
Responsible party
Sponsor
First posted
Apr 19, 2016
Start date
Apr 2016
Primary completion
Jul 2016
Completion
Jul 2016
Last update
Jul 2, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion